



**ROME MAY 7/8, 2023**  
**SECOND INTERNATIONAL**  
**SUMMIT ON LUNG CANCER**

**SCIENTIFIC COMMITTEE**  
**FEDERICO CAPPUZZO - SILVIA NOVELLO**

**SCIENTIFIC SECRETARIAT**  
**LORENZA LANDI - GABRIELE MINUTI**

09.00 **Message of IFO Scientific Director** Gennaro Ciliberto

09.10 Lecture **The evolving landscape of lung cancer** Giorgio V. Scagliotti

**PREVENTION AND EARLY DETECTION OF LUNG CANCER**

Chairs: Lucio Crinò, Fred Hirsh

09.40 **Expert's opinion** Fred Hirsh

09.45 **Tobacco cessation among patients with lung cancer** April Plank

09.55 **Early detection of lung cancer** Ugo Pastorino

**Panel Discussion**

Lucio Crinò, Fred Hirsh, Ugo Pastorino, April Plank

**LIQUID BIOPSY AND NEW BIOMARKERS**

Chairs: Jair Bar, Gabriella Sozzi

10.20 **Expert's opinion** Gabriella Sozzi

10.25 **Liquid biopsy for screening and early detection** Christian Rolfo

10.35 **Practical applications of liquid biopsy** Natasha Leigh

10.45 **Liquid biopsy for guiding therapy decision** Umberto Malapelle

10.55 **Neoantigen landscape and Tumor Mutational Burden** Patrick Alexander Ott

**Panel Discussion**

Jair Bar, Natasha Leigh, Umberto Malapelle, Patrick Alexander Ott, Christian Rolfo, Gabriella Sozzi

**NEOADJUVANT THERAPY OF LUNG CANCER**

Chairs: Domenico Galetta, Francesco Grossi, Tony Mok

11.20 **Expert's opinion** Francesco Grossi

11.25 **Chemoimmunotherapy in resectable NSCLC** Mariano Provencio

11.35 **PD-L1 expression and efficacy of neoadjuvant chemoimmunotherapy** Patrick Forde

11.45 **Neoadjuvant chemoimmunotherapy and tumor stage** Jonathan Spicer

11.55 **Post-surgery options** Nicolas Girard

12.05 **Role of MRD** Nicola Normanno

**Panel Discussion**

Patrick Forde, Domenico Galetta, Nicolas Girard, Francesco Grossi, Tony Mok, Nicola Normanno, Mariano Provencio, Jonathan Spicer

12.30 Lunch





## ADJUVANT THERAPY

Chairs: Anne-Marie C. Dingemans, Simon Eckman, Giorgio V. Scagliotti, Piergiorgio Solli

13.20 **Expert's opinion** Anne-Marie C. Dingemans

13.25 **Anti-EGFR agents in the adjuvant setting** Yi Long Wu

13.35 **Options for non-EGFR mutant/oncogene addicted resected NSCLC** Christian Grohe

13.45 **Adjuvant immunotherapy** Maurice Perol

13.55 **PD-L1 expression and choice of adjuvant immunotherapy** Enriqueta Felip Font

## 14.05 **Pannel Discussion**

Anne-Marie C. Dingemans, Simon Eckman, Enriqueta Felip Font, Christian Grohe, Maurice Perol, Giorgio V. Scagliotti, Piergiorgio Solli, Yi Long Wu

## INTEGRATED THERAPIES FOR STAGE III NSCLC

Chairs: Raffaele Califano, Andrea Filippi, Sara Ramella

14.20 **Expert's opinion** Sara Ramella

14.25 **Radiotherapy for N2 resected NSCLC** Cecile Le Pechoux

14.35 **Impact of neoadjuvant chemoimmunotherapy in management of stage III NSCLC** Marcello Tiseo

14.45 **Maintenance immunotherapy in stage III unresectable NSCLC** Umberto Ricardi

14.55 **New immunotherapy combinations as maintenance therapy after chemoradiotherapy in stage III**  
Fabrice Barlesi

## 15.05 **Pannel Discussion**

Fabrice Barlesi, Raffaele Califano, Andrea Filippi, Cecile Le Pechoux, Sara Ramella, Umberto Ricardi, Marcello Tiseo

15.20 **Lecture The voice of lung cancer patients** Anne Marie Baird

DAY 2  
MAY 8<sup>th</sup>, 2023

## IMMUNOTHERAPY FOR FIRST-LINE NSCLC

Chairs: Lorenza Landi, Mariarita Migliorino, Rolf Stahel, H. Jack West

09.00 **Expert's opinion** Rolf Stahel

09.05 **Monoimmunotherapy for advanced NSCLC PD-L1 >50%**: Ed Garon

09.15 **Mono-immunotherapy or chemo-immunotherapy in PD-L1>50%** Solange Peters

09.25 **Immunotherapy options for squamous-cell lung cancer** Miranda Gogishvili

09.35 **Immunotherapy for unfit NSCLC** Siow Ming Lee

09.45 **Combination with anti-CTLA4** Melissa Johnson

09.55 **New immunotherapy combinations** Delvys Rodriguez-Abreu

10.05 **Immunotherapy combinations for KRAS G12C mutant NSCLC** Bob LI

## 10.15 **Pannel Discussion**

Ed Garon, M. Gogishvili, Melissa Johnson, Lorenza Landi, Siow Ming Lee, Bob LI, Mariarita Migliorino, Solange Peters, Delvys Rodriguez-Abreu, Rolf Stahel, H. Jack West

## EMERGING OPTIONS IN IMMUNE-PRETREATED NSCLC

Chairs: Federico Cappuzzo, Keunchil Park, Francesco Passiglia

10.35 **Expert's opinion** Sanjesh Popat

10.40 **Mechanisms of resistance to immunotherapy** Paola Nisticò

10.50 **Novel strategies for overcoming resistance to checkpoint inhibitors**  
Judy Wang

11.00 **Targeting TAM receptors in immune-pretreated NSCLC** Ross Soo

11.10 **ADC in pretreated NSCLC** Hossein Borghaei

## 11.20 **Pannel Discussion**

Hossein Borghaei, Federico Cappuzzo, Paola Nisticò, Keunchil Park, Francesco Passiglia, Sanjesh Popa, Ross Soo, Judy Wang

## THE COLOSSEUM

Called by the ancient Romans, "Anphitheatrum Flavium" (Flavian Amphitheatre), the Colosseum is the most famous and impressive monument of ancient Rome, as well as the largest amphitheater in the world. The name is undoubtedly linked to the large size of the building but derives above all from the fact that nearby there was a colossal statue of Nero and bronze.

In 1990, the **Colosseum**, along with all the historical center of Rome, the Vatican extraterritorial zones in Italy and the Basilica of St. Paul Outside the Walls, was listed as a World Heritage Site by UNESCO, while in July 2007 was included among the New seven Wonders of the World..

## **BETWEEN IMMUNOTHERAPY AND TARGET THERAPY-ROLE OF KRAS**

Chairs: Tony Mok , Ruggero De Maria, Mark M. Awad, Stephen Liu

11.35 **Expert's opinion** Stephen Liu

11.40 **KRAS and co-mutations. Impact of STK11 or KEAP1** Ferdinandos Skoulidis

11.50 **Agents targeting KRAS G12C** Silvia Novello

12.00 **KRAS inhibitors: Single agent or in combination?** Tony Mok

12.10 **Emerging agents in KRAS mutated** Paolo Bironzo

### **12.20 Pannel Discussion**

Mark M. Awad, Paolo Bironzo, Ruggero De Maria, Stephen Liu, Tony Mok, Silvia Novello, Ferdinandos Skoulidis

12.35 Lunch

## **TARGETED THERAPIES FOR NSCLC**

Chairs: Benjamin Besse, Emilio Bria, Oliver Gautschi, Jordi Remon, Federico Cappuzzo

13.35 **Expert's opinion** Federico Cappuzzo

13.40 **Standard options for EGFR mutant NSCLC** Pasi A. Janne

13.50 **EGFR inhibitors in combination with anti-angiogenic agents** Pilar Garrido

14.00 **Impact of p53 co-mutations on EGFR-TKI efficacy** Benjamin Besse

14.10 **Drugging exon 20 mutations** Rosario Garcia Campelo

14.20 **New drugs for HER2 deregulated NSCLC** Egbert Smit

14.30 **Options for BRAF mutant patients** David Planchard

14.40 **Options for MET exon 14 mutated patients** Oliver Gautschi

14.50 **Best first-line agent for ALK + NSCLC: Who is the winner** Juergen Wolff

15.00 **Options for ROS1+ NSCLC** Lorenza Landi

15.10 **Options for NTRK rearranged tumors** Alex Drilon

15.20 **RET inhibitors in lung cancer** Roberto Ferrara

15.30 **NRG1: a new target in NSCLC** Gabriele Minuti

### **15.40 Pannel Discussion**

Benjamin Besse, Emilio Bria, Rosario Garcia Campelo, Federico Cappuzzo, Alex Drilon, Roberto Ferrara, Pilar Garrido, Oliver Gautschi, Pasi Janne, Lorenza Landi, Gabriele Minuti, David Planchard, Jordi Remon, Egbert Smit, Juergen Wolff

## **SMALL CELL LUNG CANCER AND MESOTHELIOMA**

Chairs: Andrea Ardizzoni, Fabiana Cecere, Sara Pilotto

16.00 **Expert's opinion** TBD

16.05 **Immunotherapy as first-line therapy in SCLC** Andrea Ardizzoni

16.15 **Immunotherapy combinations as first-line therapy in SCLC** Luis Paz-Ares Rodríguez

16.25 **Immunotherapy for patients with pleural mesothelioma** Paul Bass

### **16.35 Pannel Discussion**

Andrea Ardizzoni, Paul Bass, Fabiana Cecere, Luis Paz-Ares Rodríguez, Sara Pilotto

16.50 Closing Lecture **Rediscovering IHC in lung cancer** Keith Kerr

17.20 **Closing remarks** Federico Cappuzzo

### **ST. PETER'S BASILICA**

The Papal Basilica of Saint Peter in the Vatican or simply Saint Peter's Basilica is a church built in the Renaissance style located in Vatican City, the papal enclave that is within the city of Rome. It was initially planned by Pope Nicholas V and then Pope Julius II to replace the aging Old St. Peter's Basilica, which was built in the 4th century by Roman emperor Constantine the Great. Construction of the present basilica began on 18 April 1506 and was completed on 18 November 1626. Designed principally by Donato Bramante, Michelangelo, Carlo Maderno and Gian Lorenzo Bernini, St. Peter's is the most renowned work of Renaissance architecture and the largest church in the world by interior measure.

**FACULTY**

**Andrea Ardizzoni**  
Bologna - I - I

**Mark M. Awad**  
Boston - US

**Paul Baas**  
Amsterdam - NL

**Anne Marie Baird**  
Dublin - IRL

**Jair Bar**  
Tel Aviv - IL

**Fabrice Barlesi**  
Marseille - F

**Benjamin Besse**  
Paris- F

**Paolo Bironzo**  
Turin - I

**Hossein Borghaei**  
Philadelphia - US

**Emilio Bria**  
Rome - I

**Raffaele Califano**  
Manchester - UK

**Federico Cappuzzo**  
Rome - I

**Fabiana Letizia Cecere**  
Rome - I

**Gennaro Ciliberto**  
Rome - I

**Lucio Crinò**  
Meldola/Forlì - I

**Ruggero De Maria**  
Rome - I

**Anne-Marie Dingemans**  
Maastricht -NL

**Alexander Drilon**  
New York - US

**Simon Ekman**  
Uppsala - S

**Enriqueta Felip Font**  
Barcelona E

**Roberto Ferrara**  
Milan - I

**Andrea Riccardo Filippi**  
Pavia - I

**Patrick Forde**  
Baltimore - US

**Domenico Galetta**  
Bari

**Rosaria Garcia Campelo**  
Coruña - E

**Edward B. Garon**  
Santa Monica - US

**Pilar Garrido Lopez**  
Madrid - E

**Oliver Gautschi**  
Lucerna - CH

**Nicolas Girard**  
Paris- F

**Miranda Gogishvili**  
Tbilisi - GE

**Christian Grohe**  
Berlin - I

**Francesco Grossi**  
Varese - I

**Fred Hirsch**  
New York - US

**Pasi A. Janne**  
Boston - US

**Melissa Johnson**  
Nashville - US

**Keith Kerr**  
Aberdeen - UK

**Lorenza Landi**  
Rome - I

**Cecile Le Pechoux**  
Paris- F

**Natasha Leigh**  
Toronto - CDN

**Bob T. Li**  
New York - US

**Stephen Liu**  
Georgetown - US

**Umberto Malapelle**  
Naples - I

**Maria Rita Migliorino**  
Rome - I

**Siow Ming Lee**  
London - UK

**Gabriele Minuti**  
Rome - I

**Tony Mok**  
Hong Kong - RC

**Paola Nisticò**  
Rome - I

**Nicola Normanno**  
Naples - I

**Silvia Novello**  
Turin - I

**Patrick Alexander Ott**  
Boston - US

**Keunchil Park**  
Seoul - ROK

**Ugo Pastorino**  
Milan - I

**Luis Paz-Ares Rodríguez**  
Madrid - E

**Maurice Perol**  
Lione - F

**Solange Peters**  
Lausanne - CH

**Sara Pilotto**  
Verona - I

**David Planchard**  
Villejuif - F

**April Plank**  
New York - US

**Sanjesh Popat**  
London - UK

**Mariano Provencio**  
Madrid -E

**Sara Ramella**  
Rome - I

**Jordi Remon**  
Barcelona - E

**Umberto Ricardi**  
Turin - I

**Delvys Rodriguez-Abreu**  
Gran Canaria - E

**Christian Rolfo**  
New York - US

**Giorgio Vittorio Scagliotti**  
Turin - I

**Ferdinandos Skoulidis**  
Houston - US

**Egber Smit**  
Leida - NL

**Piergiorgio Solli**  
Bologna - I

**Ross Soo**  
Singapore - MY

**Gabriella Sozzi**  
Milan - I

**Jonathan Spicer**  
Montreal Trudeau - CDN

**Rolf Stahel**  
Zurich - CH

**Marcello Tiseo**  
Parma - I

**Judy Wang**  
Sarasota - US

**Howard Jack West**  
Duarte - US

**Jürgen Wolf**  
Colonia

**Yi-Long Wu**  
Guangdong - RC



## GENERAL INFORMATION

This event will take place only in person.

## VENUE

**Hotel Le Meridien Visconti Rome**

Via Federico Cesi, 37 Rome

## REGISTRATION

Registration is free of charge.

Please complete the process to register at our site [www.mitcongressi.it](http://www.mitcongressi.it)

Have a question about the upcoming conference?

Email: [segreteria@mitcongressi.it](mailto:segreteria@mitcongressi.it)

## XX ECM FOR ITALIAN PARTICIPANTS ONLY

Medical specialties:

**Pharmacy**

**Biology**

**Biomedical Technician**

**Medical Radiology Technician**

**Medical Physic**

**Surgeon** Allergy and Immunology - Genetics - Pulmonary Disease - Internal Medicine - Oncology - Radiation Oncology  
General Surgery - Thoracic Surgery - Anatomic and Clinical Pathology - Pharmacology and Medical Toxicology  
Medical Biochemical Genetics - Nuclear Medicine - Diagnostic Radiology - Hospital Clinical management  
Palliative Medicine

**Cardiocirculatory and Cardiovascular Perfusion Technician**

**Nurse**

## CME INSTRUCTIONS

The CME Questionnaire and Certificate of Participation will be available online by accessing our platform in the "My courses" section of your reserved area. For the purpose of acquiring credits, you will need 90% in person attendance and a score of 75% or higher on the learning assessment questionnaire. You must have both in person attendance and questionnaire completion to obtain credit. The deadline for the completion of the ECM assessment questionnaire and the course approval questionnaire is set within 72 hours from the end of the course.

## PROVIDER AND LOGISTIC SECRETARIAT



MI&T srl - Centro Direzionale Bolomnia

Via Guelfa, 5 - 40138 Bologna

info@mitcongressi.it - www.mitcongressi.it

UNRESTRICTED GRANT BY

